Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2026 07:58 ET | Source: Research and Markets

Cell Therapy Human Raw Materials Market Set to Surge with 12.43% CAGR, Driven by Oncological Advancements and Regenerative Medicine Investments

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Human Raw Materials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...
January 23, 2026 07:06 ET | Source: Research and Markets

Automated and Closed Cell Therapy Processing Systems Market Report 2026-2031: Analysis by Workflow, Type, Scale and Region

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added...
January 22, 2026 09:15 ET | Source: Pluri Inc.

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based...
January 21, 2026 02:46 ET | Source: Hopstem Biotechnology Inc.

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 16, 2026 05:23 ET | Source: Research and Markets

Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales

Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Cell and Gene Therapy Investment Trends" report has been added to ResearchAndMarkets.com's offering. The market size of...
January 15, 2026 11:08 ET | Source: Research and Markets

Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" has been...
January 15, 2026 09:31 ET | Source: The Juvenile Diabetes Cure Alliance

14th Annual State of the Cure for T1D Shows Major Development in Cure Research

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Juvenile Diabetes Cure Alliance (JDCA), a 501(c)(3) nonprofit solely focused on accelerating a cure for type 1 diabetes, announced the release of the 14th...
January 13, 2026 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...
January 08, 2026 08:00 ET | Source: Alps Group Inc

Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform...
January 06, 2026 09:07 ET | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Market Research Report, November 2025: Transforming US Drug Access and Production - MFN Pricing Deals and Historic Manufacturing Investments

Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, November 2025" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...